Novo Nordisk partners with OpenAI to accelerate drug development. The Danish pharmaceutical giant, maker of Wegovy and Ozempic, is deploying artificial intelligence across drug discovery, manufacturing, and commercial operations to regain ground against Eli Lilly in the lucrative weight-loss drug market. The partnership will analyze complex datasets, identify promising drug candidates, and improve manufacturing efficiency. Novo plans pilot programs across research and development with full integration by end of 2026. CEO Mike Doustdar emphasized the partnership aims to enhance scientist productivity rather than replace workers, though it may slow future hiring growth. The obesity-drug market is expected to exceed one hundred billion dollars annually within the next decade.
